1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:Demographic and clinical features of 85 patients with laboratory-proved autoimmune encephalitis, stratified by antibody group
All (n = 85) Group 1 (n = 18) Group 2 (n = 67) P Value Age (median) (IQR) 36 (24–62) 49.5 (29–64) 32 (22–61) .11 Male sex 25/85 (29%) 4/18 (22%) 21/67 (31%) .45 CSF leukocytosis 57/85 (67%) 11/18 (61%) 46/67 (69%) .69 CSF elevated protein 33/85 (39%) 11/18 (61%) 22/67 (33%) .06 Diagnosis of malignancy 15/85 (18%) 6/18 (33%) 9/67 (13%) .05 Diagnosis of teratoma/hamartoma 10/85 (12%) 2/18 (11%) 8/67 (12%) .95
Note:—IQR indicates interquartile range.